OncoMed Pharma (OMED) Reports Interim Phase 1b Results for Navicixizumab & Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
Tweet Send to a Friend
OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED) announced interim results from its ongoing Phase 1b trial investigating navicixizumab, OncoMed’s anti-DLL4/VEGF bispecific antibody ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
